From the newsletter
South African based pharmaceutical subsidiary Johnson & Johnson records fastest growth, yet again, in terms of African staff among its peers in the past year. The company has grown senior staff by 44%, or 685 new hires according to LinkedIn data. It also leads with 28% expansion in sales and business development staff, a signal of a deliberate market capture.
Pfizer follows Johnson & Johnson with 20%, then Bayer at 17%, Roche 16%, AstraZeneca 16%, GSK 14%, Novartis 12%, Sanofi 7%, Novo Nordisk 6% and Aspen Pharmacare 2%.
Compared to three months ago, Johnson & Johnson staff growth rate rose from 40% to 44%, Pfizer from 18% to 20%, and Sanofi increased from 3% to 7%. Bayer declined from 21% to 17% and Roche from 19% to 16%.
More details
The aggressive expansion by Johnson & Johnson in both senior staff and business staff signals an aggressive scaling strategy. The simultaneous rise in commercial staff suggests deliberate market capture, likely prioritising distribution strength and partnerships.
Mid-tier growth performers include Pfizer, Bayer and Roche, all recording staff growth between 16% and 20%. Notably, Pfizer’s 13% increase in sales and BD staff indicates growth driven by commercial scaling. Roche’s 14% BD expansion aligns closely with its workforce growth, pointing to balanced organisational expansion.
AstraZeneca and GSK show steady but controlled growth, each posting 14% to 16% staff increases. However, their sales and BD growth remains comparatively modest at 4% and 7%. This divergence suggests internal capacity building or pipeline preparation rather than immediate commercial push.
Slower growth is evident at Novartis and Sanofi, with staff increases of 12% and 7% respectively. Their limited BD expansion, both at 4% or below, implies consolidation phases. These firms appear to be optimising existing structures rather than pursuing rapid headcount growth.
Minimal growth is recorded by Novo Nordisk at 6% staff growth and just 2% BD increase and Aspen Pharmacare at 2% and 1% respectively. This indicates highly restrained hiring, potentially reflecting niche market focus or strategic pause rather than scaling ambition.
Our take
Most companies, except Johnson & Johnson and Pfizer, are increasing general staff without boosting sales and business development staff.
These companies risk losing ground in Africa and missing market opportunities to peers that value revenue and partnerships.